Arq vs Aspen Aerogels
Aspen Aerogels reported revenue of $271 million in fiscal 2025, 2.3 times Arq's $120 million in fiscal 2025. Arq's revenue grew 10.4% in its latest year, and Aspen Aerogels' fell 40.1%. Arq had an operating margin of -44.0%, against -139.5% at Aspen Aerogels. Free cash flow was −$11 million at Arq and −$5 million at Aspen Aerogels.
Side by side
| Arq | Aspen Aerogels | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $120M | $271M |
| Revenue growth | 10.4% | −40.1% |
| Revenue growth a year, last 5 years | 12.3% | 22.0% |
| Gross margin | 27.9% | 17.0% |
| Operating margin | −44.0% | −139.5% |
| Net margin | −43.7% | −143.7% |
| Free cash flow | −$11M | −$5M |
| Free cash flow margin | −9.4% | −1.7% |
| Return on capital | −19.9% | −93.7% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 15.2% | 2.5% |
| Last close | $2.92 | $4.87 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $561,625, sold $37,929 | sold $58.1 million |
| Piotroski F-score | 1 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ArqAspen Aerogels
Operating margin
Percent of revenue
ArqAspen Aerogels
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ArqAspen Aerogels
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arq and Aspen Aerogels pages.